INTUITIVE SURGICAL INC

Explore the July 31, 2026 snapshot of the Dow Jones Islamic Market US Titans 50 ETF: high‑growth tech focus, Shariah‑compliant holdings, and Intuitive Surgical’s niche role.

Intuitive Surgical tops Q2 expectations with 12% revenue growth, 24% operating margin and new robotic‑surgery initiatives that drive recurring software, instrument, and platform revenue.

Intuitive Surgical reports Q2 earnings that beat forecasts, driven by growing da Vinci installs and strong margins, but faces short‑term payer headwinds.

Intuitive Surgical Q2‑2026: $1.28B revenue, 42% margin, 18% EPS lift. Despite tariff and reimbursement hits, AI‑driven digital services and cost cuts fuel a resilient, growth‑oriented future.

Intuitive Surgical’s share dip amid healthcare softness, 15% Q1 revenue growth, and competitive pricing pressures – why investors keep a close eye on its roadmap.

Intuitive Surgical’s upcoming earnings reveal how its robotic‑surgery leadership, margin targets and supply‑chain resilience shape market sentiment.

Intuitive Surgical DR debuts on Thailand’s SET, giving Thai investors direct, low‑barrier access to the high‑growth U.S. medical robotics firm’s stock.

ISRG’s modest Nasdaq rally signals robust robotics demand, high margins, and AI‑driven growth amid market volatility.

Discover how Intuitive Surgical’s AI‑powered robotic surgery drives ETF growth, outpaces rivals, and taps into healthcare cost‑cutting trends.

Intuitive Surgical’s July 2 gain highlights robotic‑surgery’s proven safety, faster recoveries, and cost savings—fueling investor confidence and clinical adoption.